You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Alpha-1 Antitrypsin Gene Therapy for Cystic Fibrosis

    SBC: Generx+, Inc.            Topic: N/A

    DESCRIPTION (Applicant's Abstract): The investigators have developed a plasmid vector that expresses the normal human alpha-1 antitrypsin (AAT) gene in human respiratory epithelium when delivered as a plasmid-cationic liposome complex. In subjects with inherited AAT deficiency, they showed that liposome mediated transfer of the normal AAT gene to the nasal respiratory epi ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  2. A Novel Apoptosis Assay with Antibodies to ssDNA

    SBC: APOSTAIN, INC.            Topic: N/A

    DESCRIPTION (Provided by Applicant): Work performed during the Phase I of this project has demonstrated that formamide induces selective denaturation of DNA in apoptotic cells. This novel effect of formamide on the stability of apoptotic DNA combined with the detection of denatured DNA with monoclonal antibody (MAb)against single-stranded DNA, has made it possi ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  3. Audio-Vestibular Testing for Bedside/Other Applications

    SBC: INTELLIGENT HEARING SYSTEMS CORP            Topic: N/A

    DESCRIPTION: (Adapted from applicant's abstract): A potentially effective way of limiting or preventing drug-induced cochleo- and vestibulo-ototoxicity is monitoring during treatment. However, practical, cost-effective, monitoring programs are difficult to establish due to impractical instrumentation. Current practices also tend to neglect the balance system. Research ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  4. Controlling mechanical signal transduction to treat osteoarthritis

    SBC: Cytex Therapeutics, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Controlling mechanical signal transduction to treat osteoarthritis Abstract The TRPV4 calcium (Ca++) permeable ion channel has been shown to be expressed and functional in chondrocytes, the cells responsible for the maintenance of cartilage in weight-bearing joints. Trauma of joints with subsequent damage of cartilage, as well as chronically increased joint loa ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Derivation of Dendritic Cell-Specific Adenovirus Vectors

    SBC: VECTORLOGICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-range goal of this research project is to develop a novel and effective strategy for transduction of human dendritic cells (DC) for the purposes of genetic anti-tumor immunization. To accomplish this goal, we will develop an adenovirus(Ad)-based gene delivery system capable of efficient and specific transduction of DC ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  6. DEVELOPMENT OF MULTI-RECEPTOR LC STATIONARY PHASES

    SBC: MOLECULAR DESIGN INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION: (Applicant's description) Combinatorial methods for the synthesis of new drug substances require high throughput techniques for evaluation of structure-activity relationships. Microliter plates with immobilized target receptors can rapidly reduce thousands of possibilities to hundreds of candidates. The next level of screening has proven to be mor ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  7. Early Warning system for detecting pre-eclampsia

    SBC: CONVERGENT ENGINEERING, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): Preeclampsia, a hypertensive disorder of pregnancy, is a leading cause of maternal and neonatal morbidity and mortality around the world, responsible for approximately 76,000 maternal and 500,000 infant deaths per year.As a heterogeneous and poorly understood disorder, its pathogenesis and possible treatments are an area of active research. While the majority o ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Enteric Elimination and Degradation of Oxalic Acid

    SBC: IXION BIOTECHNOLOGY, INC.            Topic: N/A

    Approximately one million cases of stone disease are diagnosed in the United States every year and hyperoxaluria is considered to be a major risk factor. Our goal is to reduce the burden of oxalate excretion by the kidneys before the onset of renal failure caused by the oxalate-induced insults of hyperoxaluria, oxalate crystal deposition in tissue, and the formation of calcium oxalate stones. The ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  9. Establishing BRM Polymorphisms as Predictive Biomarkers for Lung Cancer Risk

    SBC: ZENAGENE, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): While there is no doubt smoking is a direct causative factor underlying the development of lung cancer, not every smoker develops lung cancer. In fact, only 10-15% of smokers develop this disease, indicating that otherfactors make certain individuals more susceptible to cancer. A number of single nucleotide polymorphisms are known to correlate with the developm ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Evaluation of a new class of molecules for treating MRSA infective endocarditis

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Patients with infective endocarditis (IE) have a poor prognosis with one third of the patients succumbing to the infection within the first year. Treatments for endocarditis involve antibiotic therapy and/or surgery that cost upwards of 100,000 per patient; however, many cases do not respond to the antibiotic treatment and surgery poses high risks. Cases of en ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government